文献速递病毒性肝炎

中国慢性乙型肝炎一线治疗的成本效果分析

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China.
PubMed 文献 · Clin Microbiol Infect · 2021-06-28

该研究构建Markov模型,比较核苷酸类似物(TAF、TDF、恩替卡韦)和聚乙二醇干扰素在中国慢性乙型肝炎患者中的成本效果,考虑满意(HBeAg血清学转换)和最优(HBsAg清除)治疗目标。结果显示,在核苷酸类似物中TDF最具成本效果,而TAF在较富裕地区具有成本效果且更有效;Peg-IFN在HBeAg阳性患者中实现满意和最优目标均最具成本效果且临床结局更好。

要点

  • 在核苷酸类似物中,TDF是中国CHB患者实现满意和最优治疗目标最具成本效果的方案。
  • TAF在较富裕地区具有成本效果且更有效,在中国东部地区达到最优目标的可接受性更高。
  • Peg-IFN在HBeAg阳性CHB患者中实现满意和最优目标均最具成本效果,且临床结局更好。

核心结论

  • 在核苷酸类似物中,TDF是中国CHB患者实现满意和最优治疗目标最具成本效果的治疗。
  • TAF具有成本效果且在较富裕地区更有效。
  • Peg-IFN在HBeAg阳性CHB患者中实现两种目标均最具成本效果,临床结局更好。

研究设计与样本

  • 构建描述CHB疾病进展的Markov模型,比较一线治疗的成本效果。
  • 比较的治疗包括TAF、TDF、恩替卡韦和Peg-IFN。
  • 考虑满意目标(HBeAg血清学转换)和最优目标(HBsAg清除)。
  • 分析主要结局包括每患者累积终身成本、增量质量调整生命年、增量成本效果比和净货币效益。
  • 进行不确定性分析以识别关键影响参数。

主要发现

  • 与基线策略相比,Peg-IFN在HBeAg阳性CHB患者实现满意和最优目标时QALY增益最高(分别为3.19和6.32)。
  • TDF在HBeAg阴性CHB患者实现满意目标时最具成本效果($1418/QALY)。
  • 在核苷酸类似物中,TAF是最有效的策略,在中国东部地区达到最优目标的可接受性更高(低于1倍人均GDP阈值)。

关键数值与推荐

  • Peg-IFN在HBeAg阳性患者实现满意目标的QALY增益为3.19。
  • Peg-IFN在HBeAg阳性患者实现最优目标的QALY增益为6.32。
  • TDF在HBeAg阴性患者实现满意目标的成本效果比为$1418/QALY。
  • TAF在中国东部地区达到最优目标的可接受性阈值低于1倍人均GDP。

临床怎么用

  • 中国CHB患者选择核苷酸类似物时,TDF为实现满意和最优目标最具成本效果的选项。
  • 在较富裕地区(如中国东部),TAF具有成本效果且更有效,可优先考虑。
  • HBeAg阳性CHB患者使用Peg-IFN实现满意和最优目标最具成本效果且临床结局更好。
  • 治疗期间和治疗后应进行定期监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hepatitis B virus infection is an important public health problem. We analysed the cost-effectiveness of the first-line therapies, including nucleotide analogues (namely tenofovir alafenamide fumarate (TAF), tenofovir disoproxil fumarate (TDF) and entecavir) and pegylated interferon (Peg-IFN) for patients with chronic hepatitis B (CHB) in China. METHODS: A Markov model describing CHB disease progression was constructed to compare the cost-effectiveness of the first-line therapies, considering both satisfactory (HBeAg seroconversion) and optimal (HBsAg seroclearance) treatment goals. We examined the main outcomes, including cumulative lifetime cost per patient, incremental quality-adjusted life years (QALYs), incremental cost-effectiveness ratio and net monetary benefit. Uncertainty analysis was conducted to identify key influential parameters. RESULTS: Compared with the baseline strategy, Peg-IFN had the highest QALY gain for HBeAg-positive (HBeAg+) CHB patients achieving a satisfactory goal and an optimal goal (3.19 and 6.32 respectively), and TDF was the most cost-effective therapy for HBeAg-negative CHB patients ($1418/QALY) achieving a satisfactory goal. Among nucleotide analogues, TAF was the most-effective strategy and had higher acceptability to achieve an optimal goal in the Eastern region of China (under 1 x GDP per capita threshold). CONCLUSIONS: Among nucleotide analogues, TDF was the most cost-effective treatment in China for CHB patients to achieve satisfactory and optimal treatment goals, whereas TAF was cost-effective and more effective in the wealthier region. Peg-IFN was most cost-effective among HBeAg+ CHB patients to achieve both goals, with better clinical outcomes. Our findings also indicate the importance of regular monitoring during and after CHB treatment, and could inform treatment strategies in China and other countries.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Dai Z, Wong IOL, Xie C, et al. Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China. Clin Microbiol Infect. 2021. PMID: 34197929. doi:10.1016/j.cmi.2021.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。